Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown ImmunoGen Inc. IMGN

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have...


Top institutional share ownership of ImmunoGen, Inc.

Name Shares Shares % change Value Value % change
Ra Capital Management, L.p. 21,741,458 0.0% $97,837 -5.5%
State Street Corp 18,199,554 32.8% $81,898 25.5%
BlackRock Inc. 17,877,269 8.8% $80,448 2.8%
Vanguard Group Inc 16,059,020 3.8% $72,266 -1.9%
Deerfield Management Company, L.p. (series C) 15,020,490 332.8% $67,592 309.2%
XBI - SPDR(R) S&P(R) Biotech ETF 14,129,253 48.5% $63,582 40.4%
Adage Capital Partners Gp, L.l.c. 11,586,193 0.0% $52,138 -5.5%
Wellington Management Group Llp 10,717,085 -18.0% $48,227 -22.4%
Redmile Group, LLC 9,141,045 -0.8% $41,135 -6.3%
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 6,455,819 2.5% $29,051 -3.1%

Top institutional buyers of ImmunoGen, Inc.

Name Shares % change Value % change Shares Value
Deerfield Management Company, L.p. (series C) 332.8% 309.2% 15,020,490 $67,592
Citadel Advisors Llc 150.8% 137.0% 1,850,041 $8,325
XBI - SPDR(R) S&P(R) Biotech ETF 48.5% 40.4% 14,129,253 $63,582
Millennium Management Llc 44.5% 36.6% 5,057,049 $22,757
State Street Corp 32.8% 25.5% 18,199,554 $81,898
VSEQX - Vanguard Strategic Equity Fund Investor Shares 21.6% 14.9% 2,896,524 $13,034
Two Sigma Advisers, Lp 14.8% 8.6% 2,826,818 $12,721
FCTDX - Strategic Advisers Fidelity U.S. Total Stock Fund 14.1% 4.3% 4,405,140 $24,845
BlackRock Inc. 8.8% 2.8% 17,877,269 $80,448
Geode Capital Management, Llc 5.6% -0.1% 3,685,781 $16,586

Top institutional sellers of ImmunoGen, Inc.

Name Shares % change Value % change Shares Value
Wellington Management Group Llp -18.0% -22.4% 10,717,085 $48,227
Granahan Investment Management Inc/ma -3.9% -9.1% 1,881,796 $8,468
Two Sigma Investments, Lp -2.9% -8.2% 2,025,627 $9,115
Northern Trust Corp -2.5% -7.8% 2,144,130 $9,648
Clearbridge Investments, LLC -2.4% -7.7% 5,372,065 $24,174
VEXMX - Vanguard Extended Market Index Fund Investor Shares -1.8% -7.2% 2,706,652 $12,180
Redmile Group, LLC -0.8% -6.3% 9,141,045 $41,135

Information provided by Fintel.io